ATE235257T1 - COMPOSITION FOR TREATING MALIGNANT TUMORS AND THEIR METASTASIS - Google Patents

COMPOSITION FOR TREATING MALIGNANT TUMORS AND THEIR METASTASIS

Info

Publication number
ATE235257T1
ATE235257T1 AT95940764T AT95940764T ATE235257T1 AT E235257 T1 ATE235257 T1 AT E235257T1 AT 95940764 T AT95940764 T AT 95940764T AT 95940764 T AT95940764 T AT 95940764T AT E235257 T1 ATE235257 T1 AT E235257T1
Authority
AT
Austria
Prior art keywords
tumor
lactose
cytotoxic
metastasis
malignant tumors
Prior art date
Application number
AT95940764T
Other languages
German (de)
Inventor
David Rubin
Original Assignee
Co Enzyme Technology Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Co Enzyme Technology Ltd filed Critical Co Enzyme Technology Ltd
Application granted granted Critical
Publication of ATE235257T1 publication Critical patent/ATE235257T1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Abstract

Growth or metastasization of malignant tumors can be inhibited by administering to a patient in need thereof sufficient lactose to block crucial lectins on the affected organ so that the tumor cells cannot anchor to other locations in the body. Lactose can be administered alone, or in combination with conjugates of cytotoxic drugs. Preferably, lactose is conjugated to a cytotoxic substance so that the primary tumor is treated concurrently with prevention of metastasis. Additionally, by conjugating a cytotoxic drug to lactose, the cytotoxic drug is maintained in close proximity to the tumor because of the receptors on the tumor which bind the lactose (and therefore the cytotoxic agent bound thereto) to the tumor cells. By using a conjugate of lactose with a cytotoxic agent, one dose is generally sufficient to destroy the receptor sites on the tumor and prevent metastasis of the tumor while treating the tumor.
AT95940764T 1994-12-21 1995-11-27 COMPOSITION FOR TREATING MALIGNANT TUMORS AND THEIR METASTASIS ATE235257T1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/360,352 US5639737A (en) 1991-11-04 1994-12-21 Method and compositions for treating malignant tumors and inhibiting growth and metastases of malignant tumors
PCT/US1995/015097 WO1996019243A1 (en) 1994-12-21 1995-11-27 Composition for treatment of malignant tumors and their metastases

Publications (1)

Publication Number Publication Date
ATE235257T1 true ATE235257T1 (en) 2003-04-15

Family

ID=23417628

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95940764T ATE235257T1 (en) 1994-12-21 1995-11-27 COMPOSITION FOR TREATING MALIGNANT TUMORS AND THEIR METASTASIS

Country Status (8)

Country Link
US (1) US5639737A (en)
EP (1) EP0797453B1 (en)
AT (1) ATE235257T1 (en)
AU (1) AU692021B2 (en)
CA (1) CA2208206C (en)
DE (1) DE69530109T2 (en)
IL (1) IL116465A (en)
WO (1) WO1996019243A1 (en)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6074643A (en) * 1993-09-09 2000-06-13 Cli Oncology, Inc. Site-directed chemotherapy of metastases
DE19524515A1 (en) * 1995-07-05 1997-01-09 Deutsches Krebsforsch Saccharide conjugates
US7087420B1 (en) 1997-07-17 2006-08-08 Cambia Microbial β-glucuronidase genes, gene products and uses thereof
US6391547B1 (en) * 1997-09-09 2002-05-21 Center For The Application Of Molecular Biology To International Agriculture Microbial β-glucuronidase genes, gene products and uses thereof
SI1098641T1 (en) * 1998-07-27 2016-08-31 St. Jude Pharmaceuticals, Inc. Chemically induced intracellular hyperthermia
DE69923322T2 (en) 1998-07-30 2005-12-22 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. USE OF PROPIONYL-L-CARNITINE AND ACETYL-L-CARNITINE FOR THE MANUFACTURE OF MEDICAMENTS WITH ANTIBODY EFFECT
US20040229908A1 (en) * 1999-07-13 2004-11-18 Jodi Nelson Compositions and methods for the treatment of Parkinson's disease and tardive dyskinesias
CA2416233A1 (en) 1999-07-13 2001-01-18 Alpha Research Group, Llc Compositions and methods for the treatment of parkinson's disease
US6548484B1 (en) * 2000-04-12 2003-04-15 International Medical Innovations, Inc. Pharmaceutical dopamine glycoconjugate compositions and methods of their preparation
US20060189547A1 (en) * 2000-04-12 2006-08-24 Christian Samuel T Novel pharmaceutical agents containing carbohydrate moieties and methods of their preparation and use
US7345031B2 (en) * 2000-04-12 2008-03-18 International Medical Innovations, Inc. Pharmaceutical dopamine glycoconjugate compositions and methods of their preparation and use
US9302982B2 (en) 2000-04-12 2016-04-05 Glycon Llc Pharmaceutical dopamine glycoconjugate compositions and methods of their preparation and use
US6642205B2 (en) 2000-09-25 2003-11-04 Pro-Pharmaceuticals, Inc. Methods and compositions for reducing side effects in chemotherapeutic treatments
JP4358515B2 (en) * 2001-04-10 2009-11-04 タカラバイオ株式会社 Therapeutic agent
US6680306B2 (en) 2001-06-21 2004-01-20 Glycogenesys, Inc. Method for enhancing the effectiveness of cancer therapies
US20040058865A1 (en) * 2001-11-26 2004-03-25 Danishefsky Samuel J Homing peptide multimers, their preparation and uses
US6916627B2 (en) * 2002-11-27 2005-07-12 St. Jude Children's Research Hospital ATM kinase compositions and methods
US20050053664A1 (en) 2003-09-08 2005-03-10 Eliezer Zomer Co-administration of a polysaccharide with a chemotherapeutic agent for the treatment of cancer
US8198328B2 (en) * 2004-01-21 2012-06-12 New York University Treatment of cancer using benzoic acid derivatives
US20060210514A1 (en) * 2005-03-18 2006-09-21 Mower Thomas E Skin protection and moisturizing compositions and method of making the same
WO2007025238A2 (en) * 2005-08-24 2007-03-01 Cedars-Sinai Medical Center Use of fructose-based therapies for the treatment of cancer
US8440695B2 (en) * 2005-11-09 2013-05-14 St Jude Children's Research Hospital Use of chloroquine to treat metabolic syndrome
EP2065057A3 (en) * 2006-03-15 2009-08-12 Mallinckrodt Inc. Chelating conjugates having a substituted aromatic moiety and derivatives thereof
WO2022112596A1 (en) 2020-11-30 2022-06-02 Cellectis Sa Use of aminoquinoline compounds for higher gene integration
CN114712521A (en) * 2022-03-22 2022-07-08 郑州大学 CD44 receptor-targeted drug, and preparation method and application thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4481195A (en) * 1978-10-13 1984-11-06 Adolf Schwimmer Method for the treatment of tumors with β-glucuronidase activity dependent pharmaceuticals
US4337760A (en) * 1978-10-13 1982-07-06 Adolf Schwimmer Method for the treatment of tumors with β-glucuronidase activity dependent pharmaceuticals
US4584368A (en) * 1978-10-13 1986-04-22 Adolf W. Schwimmer β-Glucuronidase activity and/or pH-dependent pharmaceuticals and thier methods of production
US4424348A (en) * 1978-10-13 1984-01-03 Adolf W. Schwimmer Methods of manufacture of nitrile-containing glucuronic acid conjugates
US5225542A (en) * 1984-10-23 1993-07-06 Max-Planck Gesellschaft Zur Foerderung Der Wissenschaften E.V. Specific carbohydrate-binding proteins (lectins) of mammalian tumor cells
US5239062A (en) * 1986-03-20 1993-08-24 Dana-Farber Cancer Institute, Inc. Blocked lectins, methods and affinity support for making same using affinity ligands, and method of killing selected cell populations having reduced nonselective cytotoxicity
US5395924A (en) * 1986-03-20 1995-03-07 Dana-Farber Cancer Institute, Inc. Blocked lectins; methods and affinity support for making the same using affinity ligands; and method of killing selected cell populations having reduced non-selective cytotoxicity
EP0249008B1 (en) * 1986-05-09 1993-09-15 Pulverer, Gerhard, Prof. Dr.Dr.h.c. Use of specific monosaccharides for the preparation of a medicament for the prevention of metastases of malignic tumours
US4812590A (en) * 1987-06-25 1989-03-14 Merck & Co., Inc. Carbamates of 4-hydroxyanisole as prodrugs for chemotherapy of melanoma
AU659808B2 (en) * 1990-08-30 1995-06-01 Biomembrane Institute, The Inhibition of metastasis potential and invasiveness by oligosaccharides or oligosaccharide antigens or antibodies
MX9206309A (en) * 1991-11-04 1994-05-31 David Rubin METHOD AND COMPOSITION TO TREAT TUMORS THAT HAVE HIGH ACTIVITY OF THYROSINASE.
JPH05339148A (en) * 1992-05-28 1993-12-21 T Knight Albert Substance penetrating blood-brain barrier

Also Published As

Publication number Publication date
DE69530109D1 (en) 2003-04-30
AU4240796A (en) 1996-07-10
CA2208206A1 (en) 1996-06-27
IL116465A0 (en) 1996-03-31
AU692021B2 (en) 1998-05-28
EP0797453A1 (en) 1997-10-01
IL116465A (en) 2010-04-29
US5639737A (en) 1997-06-17
WO1996019243A1 (en) 1996-06-27
DE69530109T2 (en) 2004-02-05
EP0797453B1 (en) 2003-03-26
CA2208206C (en) 2008-02-12
MX9704727A (en) 1998-06-30

Similar Documents

Publication Publication Date Title
ATE235257T1 (en) COMPOSITION FOR TREATING MALIGNANT TUMORS AND THEIR METASTASIS
Laske et al. Efficacy of direct intratumoral therapy with targeted protein toxins for solid human gliomas in nude mice
Goff et al. Treatment of ovarian cancer with photodynamic therapy and immunoconjugates in a murine ovarian cancer model
Shiah et al. Combination chemotherapy and photodynamic therapy of targetable N-(2-hydroxypropyl) methacrylamide copolymer–doxorubicin/mesochlorin e6-OV-TL 16 antibody immunoconjugates
Maris et al. Initial testing (stage 1) of sunitinib by the pediatric preclinical testing program
TR200202231T2 (en) Prevention and treatment of amyloidogenic disease
EP0740650A4 (en) Codrugs as a method of controlled drug delivery
Meyer et al. Site-specific prodrug activation by antibody-β-lactamase conjugates: regression and long-term growth inhibition of human colon carcinoma xenograft models
ATE209908T1 (en) RADICAL CAPTURER (ßSPIN TRAPSß) FOR THE TREATMENT OF DISEASES ASSOCIATED WITH OXIDATION OF LIPIDS AND PROTEINS
EA200501810A1 (en) COMPOSITION OF CONJUGATED MEDICINE
EP1434603A4 (en) Method of treatment using ligand-immunogen conjugates
WO2002013873A3 (en) P97-active agent conjugates and their methods of use
BR9713197A (en) Means for treating prostate hypertrophy and prostate cancer
Ning et al. Radiosensitization by intratumoral administration of cisplatin in a sustained-release drug delivery system
TR200101174T2 (en) 5HT1, receptor agonists and metoclopramide for migraine treatment.
ES2173641T3 (en) COMPOSITION OF OPIACE DERIVATIVES FOR THE MANUFACTURE OF MEDICINES.
WO1999056723A3 (en) Hemoglobine-haptoglobin complexes for targeted drug delivery
DE602004016376D1 (en) COMBINATION OF ET-743 WITH 5-FLUOROURACIL PRO DRUGS FOR THE TREATMENT OF CANCER
Philpott et al. Improved selective cytotoxicity with an antibody-diphtheria toxin conjugate
Pearson et al. Chemoimmunotoxin therapy against a human colon tumor (HT-29) xenografted into nude mice
AR016427A1 (en) USEFUL CONJUGATES FOR THE TREATMENT OF PROSSTATA CANCER, AND A PHARMACEUTICAL COMPOSITION THAT UNDERSTANDS THEM.
Myklebust et al. Targeted therapy with immunotoxins in a nude rat model for leptomeningeal growth of human small cell lung cancer
Epstein et al. Use of the immunotoxin N901‐blocked ricin in patients with small‐cell lung cancer
WO2001041747A3 (en) Pharmaceutical preparation containing cytostatic agents and electron acceptors for treating cancer
Prados Temozolomide in combination with other cytotoxic agents

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties